;
Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Aspen, Mylan deal

    Aspen Pharmacare Holdings Ltd. (JSE:APN), Durban, South Africa Mylan Inc. (NASDAQ:MYL), Canonsburg, Pa. Business: Hematology Mylan's Mylan Ireland Ltd. subsidiary acquired U.S. rights to Arixtra fondaparinux and the …

    Published on 9/29/2014
  • AstraZeneca, Cancer Research UK deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Cancer Research UK, London, U.K. Business: Cancer Cancer Research UK and AstraZeneca's MedImmune LLC unit will establish a joint laboratory to discover and develop …

    Published on 9/29/2014
  • BeiGene, Merck KGaA deal

    BeiGene Co. Ltd., Beijing, China Merck KGaA (Xetra:MRK), Darmstadt, Germany Business: Cancer BeiGene received a $9 million milestone payment from Merck's Merck Serono S.A. unit under a 2013 deal granting Merck exclusive…

    Published on 9/29/2014
  • Biodesix, Blue Cross Blue Shield deal

    Biodesix Inc., Broomfield, Colo. Blue Cross and Blue Shield Association, Chicago, Ill. Business: Diagnostic Biodesix said that Blue Cross Blue Shield's Highmark Inc. affiliate issued a positive coverage decision for …

    Published on 9/29/2014
  • BioInvent, Bayer deal

    BioInvent International AB (SSE:BINV), Lund, Sweden Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Pharmaceuticals BioInvent received an undisclosed milestone payment from Bayer under a 2008 deal granting the …

    Published on 9/29/2014
  • Circle Pharma, Pfizer deal

    Circle Pharma Inc., San Francisco, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Pharmaceuticals Circle partnered with Pfizer to design and develop macrocyclic peptides against two undisclosed Pfizer targets. …

    Published on 9/29/2014
  • Civitas, Acorda deal

    Civitas Therapeutics Inc., Chelsea, Mass. Acorda Therapeutics Inc. (NASDAQ:ACOR), Ardsley, N.Y. Business: Neurology Neurological disorder company Acorda will acquire Civitas for $525 million in cash. Civitas' CVT-301 is…

    Published on 9/29/2014
  • Diametra, Immunodiagnostic Systems deal

    Dia.Metra S.r.l., Milan, Italy Immunodiagnostic Systems Holdings plc (LSE:IDH), Boldon, U.K. Business: Diagnostic Immunodiagnostic Systems acquired diagnostic company Dia.Metra (dba Diametra) for an undisclosed upfront …

    Published on 9/29/2014
  • Epirus, Livzon, Joincare deal

    Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS), Boston, Mass. Livzon Pharmaceutical Group Inc. (SZSE:000513;HKSE:1513), Zhuhai, China Joincare Pharmaceutical Group Industry Co. Ltd. (Shanghai:600380), Shenzhen, China …

    Published on 9/29/2014
  • ImmunoGenes, Kyowa Hakko Kirin deal

    ImmunoGenes AG, Zug, Switzerland Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Business: Pharmaceuticals ImmunoGenes granted Kyowa Hakko a non-exclusive license to use ImmunoGenes' transgenic mouse technology to…

    Published on 9/29/2014
  • Ligand, CURx Pharmaceuticals deal

    Ligand Pharmaceuticals Inc. (NASDAQ:LGND), La Jolla, Calif. CURx Pharmaceuticals Inc., San Diego, Calif. Business: Neurology Ligand expanded an August 2013 deal with CURx to include the development and commercialization…

    Published on 9/29/2014
  • MedGenesis, Pfizer deal

    MedGenesis Therapeutix Inc., Victoria, B.C. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Neurology, Drug delivery MedGenesis granted Pfizer an exclusive, worldwide option to license glial cell line-derived …

    Published on 9/29/2014
  • Merrimack, Baxter deal

    Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), Cambridge, Mass. Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Business: Cancer Merrimack granted Baxter exclusive rights outside of the U.S. and Taiwan to develop …

    Published on 9/29/2014
  • Navidea, Hainan Sinotau Pharmaceutical deal

    Navidea Biopharmaceuticals Inc. (NYSE-M:NAVB), Dublin, Ohio Hainan Sinotau Pharmaceutical Co. Ltd, Beijing, China Business: Diagnostic Navidea granted Hainan Sinotau exclusive rights in China, excluding Hong Kong and …

    Published on 9/29/2014
  • QLT, Auxilium deal

    QLT Inc. (TSX:QLT;NASDAQ:QLTI), Vancouver, B.C. Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL), Chesterbrook, Pa. Business: Ophthalmic Auxilium's board unanimously reaffirmed its proposed merger with ophthalmic play QLT in…

    Published on 9/29/2014
  • Saniona, NeuroSearch, J&J deal

    Saniona AB (AktieTorget:SANION), Ballerup, Denmark NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Neurology Saniona and Johnson & Johnson's Janssen …

    Published on 9/29/2014
  • Sarepta Therapeutics, Flagship Biosciences deal

    Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Flagship Biosciences LLC, Westminster, Colo. Business: Musculoskeletal Sarepta partnered with Flagship to develop automated quantitative endpoint measurements in…

    Published on 9/29/2014
  • Sigma-Aldrich, Merck KGaA deal

    Sigma-Aldrich Corp. (NASDAQ:SIAL), St. Louis, Mo. Merck KGaA (Xetra:MRK), Darmstadt, Germany Business: Supply/Service Merck will acquire Sigma-Aldrich for $140 per share in cash, or about $17 billion. The price is a 37%…

    Published on 9/29/2014
  • Tau Therapeutics, Xdynia deal

    Tau Therapeutics LLC, Charlottesville, Va. Xdynia LLC, Charlottesville, Va. Business: Neurology, Cancer Tau Therapeutics and Xdynia merged to form Cavion LLC. In 2012, Tau launched Xdynia to develop calcium channel T-…

    Published on 9/29/2014
  • University of New Mexico, SolaranRx deal

    University of New Mexico, Albuquerque, N.M. SolaranRx Inc., Albuquerque, N.M. Business: Cancer SolaranRx received an exclusive option from the university to license exclusive, worldwide rights to preclinical …

    Published on 9/29/2014
  • Vidara Therapeutics, Horizon Pharma deal

    Vidara Therapeutics International Ltd., Dublin, Ireland Horizon Pharma Inc., Deerfield, Ill. Business: Autoimmune, Musculoskeletal, Inflammation Specialty pharma Horizon Pharma completed its acquisition of Vidara …

    Published on 9/29/2014
  • Altor BioScience, Shenzhen Beike Biotechnology deal

    Altor BioScience Corp., Miramar, Fla. Shenzhen Beike Biotechnology Co. Ltd., Shenzhen, China Business: Cancer Altor granted Shenzhen Beike rights in China to develop and commercialize ALT-803 for human indications. The …

    Published on 9/22/2014
  • AstraZeneca, Eli Lilly deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Neurology Eli Lilly and AstraZeneca partnered to jointly develop and commercialize AZ's AZD3293 worldwide for …

    Published on 9/22/2014
  • Asuragen, J&J deal

    Asuragen Inc., Austin, Texas Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Supply/Service, Genomics Johnson & Johnson's Janssen Diagnostics LLC subsidiary gained worldwide rights to offer next-generation …

    Published on 9/22/2014
  • Boehringer Ingelheim, BeiGene deal

    Boehringer Ingelheim GmbH, Ingelheim, Germany BeiGene Co. Ltd., Beijing, China Business: Cancer, Biomanufacturing Boehringer partnered with BeiGene to manufacture biopharmaceuticals for BeiGene's clinical trials for …

    Published on 9/22/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993